Furthermore, P.pAb-P.pAb and T-tau were quantified for a subset of baseline plasma samples from AD decliners (n = 13) and AD non-decliners (n = 17), based upon cognitive decline over a 12-month period. This evidence concerns the gene MAPT and Alzheimer disease.